
    
      Part A (NG-641 monotherapy): Up to 18 patients will be dosed with intravenous NG-641.
      Patients will then proceed to planned surgical resection.

      Part B (NG-641 and pembrolizumab): Up to 30 patients will be dosed with intravenous NG-641
      before receiving a single dose of pembrolizumab. Patients will then proceed to planned
      surgical resection.
    
  